The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2016KH176 as a Novel Disease-modifying Therapeutic for Parkinson’s Disease
Study Rationale:
Mitochondrial dysfunction has a prominent role in the process of Parkinson’s disease (PD). Mutations in at least seven genes are known to underlie PD, most of them encode proteins that... -
Therapeutic Pipeline Program, 2016Long-term Cell Restorative Treatment for Parkinson’s Disease
Study Rationale:
Cell replacement therapies for Parkinson’s disease (PD) propose to replace the lost dopaminergic neurons in the brain. Transplanted fetal dopamine neurons have... -
Therapeutic Pipeline Program, 2016USP13 Regulation of Parkin Stability
Study Rationale:
Our data show that the enzyme USP13 is dramatically increased (two-fold) in sporadic Parkinson’s brains, and cell culture studies suggest that USP13 de-ubiquitinates... -
Target Advancement Program, 2016Targeting the Transcriptional Regulator of Autophagy LMX1B for Parkinson's Disease Therapeutic Development
Study Rationale:
LMX1B is a transcription factor that plays an essential role in the development of dopaminergic neurons. We have recently described a new role for LMX1B in dopaminergic neurons as a... -
Target Advancement Program, 2016Role of LRRK2 in GCase-mediated Alterations in Lysosome Function and Alpha-synuclein Metabolism
Study Rationale:
Mutations in the lysosomal (enzyme storage unit) enzyme GCase are associated with an increased risk of Parkinson's disease (PD) and cause alpha-synuclein (protein associated with... -
Improved Biomarkers and Clinical Outcome Measures, 2016Brainstem and Olfactory System Biomarkers of Early Parkinson's Disease
Study Rationale:
There is a great need to identify Parkinson's disease (PD) in its earliest stages when interventions may prevent or slow neural degeneration. Given that the earliest brain pathology...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.